Avoid. TEVA scores 36.8 on Growth Compounder and 34 on Value Compounder—well below median—signaling neither growth nor deep value appeal. Leadership Alignment at 53.3 suggests moderate but uncompelling governance, while the Vulnerable profile reflects structural exposure to generic drug pricing pressure and patent cliffs with limited competitive moat. Even at 13.3× forward P/E, the risk-reward lacks sufficient margin of safety.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Teva Pharmaceutical Industries :
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 31/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Teva Pharmaceutical Industries (TEVA) at 31/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. TEVA scores 36.8 on Growth Compounder and 34 on Value Compounder—well below median—signaling neither growth nor deep value appeal. Leadership Alignment at 53.3 suggests moderate but uncompelling governance, while the Vulnerable profi
TEVA's current Stocky Verdict is 31/100, placing it in the "Avoid" band. This composite combines a 37/100 Compounder score, 53/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Teva Pharmaceutical Industries yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Teva Pharmaceutical Industries scores 53/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Teva Pharmaceutical Industries 's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Teva Pharmaceutical Industries .
Sign up free and unlock the full analysis on TEVA — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for TEVA in the app.
